Sirtex develops oncology treatments using small particle technology to improve outcomes for patients with cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation during minimally invasive Selective Internal Radiation Therapy. Data shows a 7.9-month improvement in Progression-Free Survival in the liver for patients with unresectable mCRC treated 1st-line with SIR-Spheres Y-90 resin microspheres plus standard chemotherapy. The results of the 530-patient SIRFLOX randomized controlled study opens new treatment possibilities for patients whose tumors cannot be resected. Learn more about the SIRFLOX study and its significance for patients at www.sirtex.com/SIRFLOX.
300 Unicorn Park Drive
Woburn, Massachusetts 01801